Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56

Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.